Ipamorelin + CJC-1295 (10mg)

The Ipamorelin + CJC-1295 (no DAC) Blend is a co-lyophilized dual-peptide research compound combining two growth hormone secretagogues that operate through complementary receptor pathways. Ipamorelin (Aib-His-D-2Nal-D-Phe-Lys-NH2, MW ~711 Da) is a selective GHS-R1a agonist, while CJC-1295 without Drug Affinity Complex is a modified growth hormone-releasing hormone (GHRH) analogue consisting of 29 amino acids (MW ~3,367 Da) with amino acid substitutions at positions 2, 8, 15, and 27 that enhance metabolic stability.

Research interest in this combination stems from the dual-pathway hypothesis: ipamorelin activates the ghrelin receptor pathway on pituitary somatotrophs while CJC-1295 engages the GHRH receptor (GHRHR), a class B GPCR that signals through cAMP/PKA cascades. Preclinical studies have investigated whether simultaneous activation of both receptor systems produces amplified, synergistic GH secretion compared to either compound alone. Research has also examined the pulsatile nature of GH release achieved through this dual-agonist approach.

This blend provides researchers with a single-vial preparation for dual-receptor GH axis studies, eliminating the need for separate reconstitution and co-administration timing.

Viking Labs co-lyophilizes both peptides at a USA-based cGMP facility. Dual-analyte HPLC analysis confirms 99%+ purity for each component. Certificate of Analysis included, batch serialized, sterile filled.

Storage: Store lyophilized at -20C. Reconstituted at 2-8C, use within 21 days.

For laboratory research use only. Not for human consumption.